Targeted Anticancer Flashcards

1
Q

Target of Bevacizumab

A

VEGF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

2 TKI’s associated with cardiovascular dysfunction

A

Lapatinib, Nilotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Administration of Bortezomib

A

IV Bolus or SC Injection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

All currently available Tyrosine Kinases inhibitors work by

A

Binding to the highly-conserved ATP-binding site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Bevacizumab Toxicities

A

HTN, CHR, Pulmonary Hemorrhage, GI perforation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Block heterodimerization of Her2 and Her3

A

MOA of Pertuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Blood dyscriasis should be immediately associated with

A

Cytotoxic Agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Function of 26-S proteosome

A

Inhibit degradation of proteins marked by ubiquitin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MOA of Everolimus

A

mTOR inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MOA of Ipiliumumab

A

Stimuates T-Cell activation by binding CTLA-4 on surface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA of Pertuzumab

A

Block heterodimerization of Her2 and Her3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA of Sirolimus

A

mTOR inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MOA of Temsirolimus

A

mTOR inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

mTOR inhibitors

A

Sirolimus, Everolimus, Temsirolimus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Patients with mutations in KRAS and BRAF are less likely to respond to

A

Anti-EGFR therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Prevents binding of first generation tyrosine kinase inhibitors

A

Significance of T315I mutation

17
Q

Significance of T315I mutation

A

Prevents binding of first generation tyrosine kinase inhibitors

18
Q

Stimuates T-Cell activation by binding CTLA-4 on surface

A

MOA of Ipiliumumab

19
Q

Target of Bortezomib

A

26-S Proteosome

20
Q

Target of Cetuximab

A

EGFR

21
Q

Target of Ipilumumab

A

CTLA-4

22
Q

Target of Ofatumumab

A

CD20

23
Q

Target of Panitumumab

A

EGFR

24
Q

Target of Rituximab

A

CD20

25
Q

Target of Trastuzumab

A

Her-2

26
Q

TKI inhibitors w/ common Thyroid Dysfunction

A

Sorafenib, Sunitibin, Imatinib

27
Q

Toxicities of Cetuximab

A

Infusion, skin rash with sun

28
Q

Toxicities of Ofatumumab

A

Infusion reaction, Infections, Progressive Leukoencephalopathy

29
Q

Toxicities of Rituximab

A

Infusion reaction, B-cell depletion, Lymphopenia

30
Q

Toxicities of Trastuzumab

A

Cardiomyopathy, (infusion reaction)

31
Q

Transcription factor that induces VEGF

A

HIF-1

32
Q

What targets 26-S Proteosome

A

Bortezomib

33
Q

What targets CD20

A

Rituximab, Ofatumumab

34
Q

What targets CTLA-4

A

Ipilumumab

35
Q

What targets EGFR

A

Cetuximab, Panitumumab

36
Q

What targets Her-2

A

Trastuzumab

37
Q

What targets VEGF

A

Bevacizumab

38
Q

What to monitor with TKI’s

A

Thyroid Function, Bone Density, Blood Glucose in Diabetics